NCT06997796 Treatment of Nosebleeds in the Emergency Department With Powder Tranexamic Acid
| NCT ID | NCT06997796 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Dr. Anne Conlin |
| Condition | Epistaxis Nosebleed |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-05 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2025-05 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Nosebleeds are very common, occurring in 60% of the population; in some patients, nosebleeds are a life-threatening emergency. To stop a nosebleed in the emergency department, doctors usually have to burn the nose (called cauterization) or insert pledgets (called nasal packing) into the nose to apply direct pressure to the bleeding site. Nasal packing can cause pain and discomfort at the time it is inserted in the nose and again when it is removed. In rare cases it can cause a range of complications: minor complications include scar bands in the nose, but serious complications of nasal packing have also occurred, including death. Nasal packing can also present risks to doctors, such as the risk of contracting airborne and bloodborne infections, like COVID-19 and HIV. Tranexamic acid in pill form or given directly into a vein is a medication that is currently used for nosebleeds. This study looks to evaluate if tranexamic acid in powder form sprayed directly in the nose can be used as an alternative to cauterization or nasal packing for the treatment of nosebleeds.
Eligibility Criteria
Inclusion Criteria: * Capable of giving informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Adults 18 years or older * Male or female * Presenting to the ED with active, spontaneous epistaxis. Anterior versus posterior epistaxis will be identified a priori. Anterior epistaxis is operationally defined as active nasal bleeding that occurs anterior to the anterior limit of the middle turbinate, visible by anterior rhinoscopy. Exclusion Criteria: * Prior sinonasal surgery within the preceding 1 month. * Patients who required medical treatment for epistaxis in the preceding 30 days. * Septum perforation. * Known history of bleeding disorders, including thrombocytopenia, hemophilia, hereditary hemorrhagic telangiectasia, or von Willebrand disease. * History of known thromboembolic disease, including subarachnoid hemorrhage, stroke, or TIA. * Known history of disease of the central nervous system, including seizures, convulsions, or intra-cerebral disease processes/lesions. * Known or suspected history of significant skull base trauma, including skull base fracture or cerebrospinal fluid leak. * Known history of acquired disturbances of colour vision. * Known hematuria or any bleeding related to the kidney. * Pregnant and/or lactating women. * History of known allergy or sensitivity to the study medication. * Presence of signs or symptoms of concomitant emergent conditions, including myocardial infarction, stroke, major trauma, shock, or hemodynamic instability. * Patients with other medical conditions including cognitive limitations or impairment due to substance abuse. * Patients with any other condition that, in the opinion of the investigator, may present an unreasonable risk to the patient, may make the patient unreliable, or may interfere with the study assessments. * Current participation in another interventional clinical trial.
Contact & Investigator
Anne Conlin, Assistant Professor, University of Ottawa, HBA&Sc, MD, FRCSC
PRINCIPAL INVESTIGATOR
Peterborough Regional Health Center; University of Ottawa
Frequently Asked Questions
Who can join the NCT06997796 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Epistaxis Nosebleed. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06997796 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06997796 currently recruiting?
Yes, NCT06997796 is actively recruiting participants. Contact the research team at aconlin@prhc.on.ca for enrollment information.
Where is the NCT06997796 trial being conducted?
This trial is being conducted at Peterborough, Canada.
Who is sponsoring the NCT06997796 clinical trial?
NCT06997796 is sponsored by Dr. Anne Conlin. The principal investigator is Anne Conlin, Assistant Professor, University of Ottawa, HBA&Sc, MD, FRCSC at Peterborough Regional Health Center; University of Ottawa. The trial plans to enroll 24 participants.